Methods for regulating hematopoietic cell differentiation with polymers containing disaccharide units
AssigneeInstitut National De La Sante Et De La Recherche Medial (Inserm)
InventorsFlorence Smadja-Joffe, Rachida-Sihem Charrad, Christine Chomienne, Bertrand Delpech, Claude Jasmin
Life of this patent
Estimating the term…
Abstract
The invention concerns the use of a polymer comprising an efficient amount of disaccharide units each consisting of a molecule with N-acetyl-D-glucosamine structure bound by the O-glucoside β1,4 linkage to a molecule with glucuronic acid structure for producing a medicine designed to induce or stimulate the differentiation of hematopoietic cells, and leukemic cells in particular.
Claims33
An in vitro method of regulating the differentiation of hematopoietic cells comprising contacting said hematopoietic cells with a differentiation regulating amount of a composition comprising a polymer, said polymer comprising disaccharide units each comprised of an N-acetyl D-glucosamine structure molecule bonded by an O-glycoside β1,4 bond with a glucouronic acid structure molecule, such that differentiation of said hematopoietic cells are regulated.
A method of treating a person suffering from at least one of leukaemia, aplasia and neutropenia, said method comprising administering to said person a hematopoietic cell stimulating amount of a composition comprising a polymer, said polymer comprising disaccharide units each comprised of a N-acetyl D-glucosamine structure molecule bonded by an O-glycoside β1,4 bond with a gluceuronic acid structure molecule, such that said hematopoietic cells are stimulated or induced to differentiate.
A medicinal product intended to induce or stimulate the differentiation of cells selected from the group consisting of leukaemic cells and CD14 negative/CD15 negative stem cells, said product comprising a polymer comprising an effective quantity of disaccharide units each composed of an N-acetyl-D-glucosamine structure molecule bonded by an O-glycoside β1, 4 bond with a glucuronic acid structure molecule, and anti-ICAM1 monoclonal antibody or an ICAM1 binding fragment thereof.
A method of producing a medicinal product intended to induce or stimulate the differentiation of cells selected from the group consisting of leukaemic cells and CD14 negative/CD15 negative stem cells, said method comprising admixing in said medicinal product a polymer comprising an effective quantity of disaccharide units each composed of an N-acetyl-D-glucosamine structure molecule bonded by an O-glycoside β1, 4 bond with a glucuronic acid structure molecule, and an adjuvant involved in myeloid differentiation, wherein said adjuvant comprises an anti-CD44 antibody or a CD44-binding fragment thereof.
A medicinal product intended to induce or stimulate the differentiation of cells selected from the group consisting of leukaemic cells and CD14 negative/CD15 negative stem cells, said medicinal product comprising a polymer comprising an effective quantity of disaccharide units each composed of an N-acetyl-D-glucosamine structure molecule bonded by an O-glycoside β1, 4 bond with a glucuronic acid structure molecule, and an adjuvant involved in myeloid differentiation.
A method for predicting the therapeutic benefit of a medicinal product intended to induce or stimulate the differentiation of cells selected from the group consisting of leukaemic cells and CD14 negative/CD15 negative stem cells, said method comprising placing in contact under physiological conditions leukaemic blasts from a patient and said medicinal product, determining whether said blasts differentiate in vitro, and predicting from said determination whether said product will be therapeutically beneficial to said patient.
Dependencies are inferred from the claim text.